2 dated analysis items. Most recent: Fewer than a fifth of priced programs will name the pharmacy that makes your medicine (2026-08-05).
Analysis items are our own work on the dataset rather than reporting on someone else's announcement.
Why analysis developments matter here
They exist because the most useful findings in this category are usually about the information itself: how often published prices are wrong, in which direction, and what structural incentive produces the error.
Every analysis names its method and links the underlying data, so the conclusion can be recomputed rather than trusted.
All analysis items
Fewer than a fifth of priced programs will name the pharmacy that makes your medicine
We scored every tracked programme on what it publishes before you pay. The results are worse…
Who actually makes your medicine: three ownership structures, three risk profiles
Owned pharmacy, single contracted partner, or several named partners. The difference only…
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.